IFRX (IFRX) Stock Price & Analysis
IFRX (IFRX) rose 0.58% to USD 1.74 as of July 26, 2026 at 19:39 UTC, according to Nexqual real-time market data.
IFRX last closed at USD 1.73; the session ranged USD 1.7–1.79 on volume of 823,297 shares. Market capitalization is $256.29M, with a 52-week range of USD 0.74–2.95 (NMS). Source: Nexqual, July 26, 2026 at 19:39 UTC.
Key Statistics (as of July 26, 2026 at 19:39 UTC)
| Price | USD 1.74 |
|---|---|
| Change | ▲ 0.58% (up) |
| Previous Close | USD 1.73 |
| Open | USD 1.76 |
| Day Range | USD 1.7 – 1.79 |
| 52-Week Range | USD 0.74 – 2.95 |
| Volume | 823,297 shares |
| Market Cap | $256.29M |
| Exchange | NMS |
Technical Analysis (IFRX)
Nexqual's technical model rates IFRX "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 26, 2026 at 19:39 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 37.05 (neutral) |
| vs SMA50 | Below (USD 2.06) |
| MACD | -0.07 (negative) |
Analyst Ratings (IFRX)
Wall Street analysts rate IFRX "Strong Buy" based on 8 analysts, with a mean price target of USD 7.43 (range USD 2.9–13.53), per Nexqual as of July 26, 2026 at 19:39 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 7.43 |
| High Target | USD 13.53 |
| Low Target | USD 2.9 |
| Buy / Hold / Sell | 7 / 1 / 0 |
Earnings (IFRX)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -0.06 |
| Revenue Estimate | $3,500 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.08 vs est -0.15 ▲ beat |
| 2025-12-31 | USD -0.15 vs est -0.15 ▼ miss |
| 2025-09-30 | USD -0.18 vs est -0.12 ▼ miss |
| 2025-06-30 | USD -0.21 vs est -0.2 ▼ miss |
Source: Nexqual, July 26, 2026 at 19:39 UTC.
Financials & Fundamentals (IFRX)
| Total Revenue | $29,331 |
|---|---|
| Gross Margin | +0.00% |
| Operating Margin | -144769.81% |
| Profit Margin | +0.00% |
| ROE | -79.94% |
| Debt / Equity | 2.23 |
| Current Ratio | 4.16 |
| Total Cash | $39.80M |
| Total Debt | $823,028 |
| Free Cash Flow | $-15.89M |
Source: Nexqual, July 26, 2026 at 19:39 UTC.
Financial Health Score (IFRX)
Nexqual rates IFRX's overall financial health "Weak" across five dimensions, as of July 26, 2026 at 19:39 UTC.
| Growth | Critical — Revenue -82% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $40M cash, no debt |
| Cash Flow | Weak — FCF negative: -$16M, burning cash |
| Efficiency | Critical — ROE -80%, ROA -39.1% |
Ownership (IFRX)
| Insider Ownership | +2.95% |
|---|---|
| Institutional Ownership | +30.30% |
| Shares Outstanding | 147.29M |
| Float | 55.47M |
| Short % of Float | +6.57% |
Source: Nexqual, July 26, 2026 at 19:39 UTC.
Leadership (IFRX)
IFRX is led by Niels C. Riedemann (age 52), Co-Founder, CEO & Executive Director, per Nexqual as of July 26, 2026 at 19:39 UTC.
| Co-Founder, CEO & Executive Director | Niels C. Riedemann (age 52) |
|---|---|
| Co-Founder, Chief Scientific Officer & Executive Director | Renfeng Guo (age 55) |
| Chief Financial Officer | Thomas Taapken (age 60) |
| Senior Director and Head of Drug Safety & Pharmacovigiliance | Peter Hurt |
| Senior Director & Head of IT | Daniel Vetter |
Major Backers & Investors (IFRX)
Notable institutional backers of IFRX include Suvretta Capital Management, LLC, 683 Capital Management LLC, Fidelity, according to Nexqual as of July 26, 2026 at 19:39 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Suvretta Capital Management, LLC | 10.97% |
| 683 Capital Management LLC | 4.59% |
| Fidelity | 4.48% |
| Bank of America Corporation | 2.73% |
| Eversept Partners, LP | 2.43% |
| Morgan Stanley | 1.63% |
| Marshall Wace LLP | 0.77% |
| Raymond James Financial, Inc. | 0.55% |
Source: Nexqual, July 26, 2026 at 19:39 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| IMUX | Immunic, Inc. | USD 13.39 | ▼ 11.38% |
| CYPH | Cypherpunk Technologies Inc. | USD 0.62 | ▼ 7.44% |
| CRVS | Corvus Pharmaceuticals, Inc. | USD 13.07 | ▼ 6.58% |
| CYCN | Cyclerion Therapeutics, Inc. | USD 3.5 | ▼ 3.58% |
| IMMP | Immutep Limited | USD 0.38 | ▼ 1.41% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 26, 2026 at 19:39 UTC. This page is informational and not investment advice.